SEC Form 4

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287

	onib Hambon	0200	020.
	Estimated average burd	en	
	hours per response:		0.5
Ľ			

C/O TANDEN (DIADETEC CADE INC			2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC TNDM		tionship of Reporting Perso (call applicable) Director Officer (give title below)	n(s) to Issuer 10% Owner Other (specify below)
			3. Date of Earliest Transaction (Month/Day/Year) 02/16/2016	E	VP, CHIEF OPERATIN	NG OFFICER
(Street) SAN DIEGO (City)	CA (State)	92121 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Filing (Form filed by One Report Form filed by More than C Person	ing Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities / Disposed Of (5)					7. Nature of Indirect Beneficial Ownership (Instr. 4)
	Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(instr. 4)			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options ⁽¹⁾	\$6.95	02/16/2016		A		84,600		(2)	(3)	Common Stock	84,600	\$0.00	84,600	D	

Explanation of Responses:

1. Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.

2. All shares subject to the option will vest as to 25% on 2/16/2017 and the remainder in 36 equal monthly installments thereafter.

3. The expiration date for these options is 10 years from the date of grant.

Remarks:

/s/ David B. Berger, Attorneyin-Fact for John F. Sheridan

** Signature of Reporting Person

02/17/2016

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.